Company: AGIO
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0001439222-25-000036
Chunk: 81

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-05-01
Form: 10-Q
Item: Part I, Item 1
Chunk 81
---
,021,549 $45.85 Vested and expected to vest at March 31, 20256,378,183 $40.73 At March 31, 2025, there was approximately $38.1 million of total unrecognized compensation expense related to unvested stock option awards, which we expect to recognize over a weighted-average period of approximately 2.81 years.Restricted stock unitsThe following table presents RSU activity for the three months ended March 31, 2025:Number ofStock UnitsWeighted-AverageGrant Date Fair ValueUnvested shares at December 31, 20241,818,563 $30.31 Granted1,056,231 33.20 Vested(676,891)29.77 Forfeited(26,376)29.82 Unvested shares at March 31, 20252,171,527 $31.89 As of March 31, 2025, there was approximately $61.2 million of total unrecognized compensation expense related to RSUs, which we expect to recognize over a weighted-average period of approximately 2.30 years.Performance-based stock units The following table presents PSU activity for the three months ended March 31, 2025:Number ofStock UnitsWeighted-AverageGrant Date Fair ValueUnvested shares at December 31, 2024374,583 $29.45 Granted185,450 33.12 Unvested shares at March 31, 2025560,033 $30.67 Stock-based compensation expense associated with these PSUs is recognized if the underlying performance condition is considered probable of achievement using our management’s best estimates.As of March 31, 2025, there was no unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered probable of achievement, and $17.2 million of total unrecognized compensation expense related to PSUs with performance-based vesting criteria that are considered not probable of achievement.2013 Employee Stock Purchase PlanIn June 2013, our Board of Directors adopted, and in July 2013 our stockholders approved, the 2013 Employee Stock Purchase Plan, or the 2013 ESPP. We issued and sold 52,092 and 52,514 shares of common stock during the three months ended March 31, 2025 and 2024, respectively, under the 2013